Cardiac Amyloidosis Workshop

CA Overview

Case-Based Approach to Diagnosis and Management of Cardiac Amyloidosis 

7:30 am – 11:30 am | Friday, April 12, 2019 | Palm Harbor, Fla.

Precedes NC Today 2019
If you plan to attend NC Today, you may add this program for no additional charge within that registration.

 

"Cardiac Amyloidosis Overview Only" Registration Fee: $99

 

Cardiac Amyloidosis Overview

This half-day CME case-based program will explore the diagnosis and management of cardiac amyloidosis. After an overview of the biological basis of cardiac amyloidosis, an interactive case-based panel discussion will address the challenges of disease presentation, the role of various imaging modalities in the diagnosis, including a detailed discussion of technetium-99m pyrophosphate imaging and an overview of current and emerging treatments for transthyretin cardiac amyloidosis. The availability of new treatments has enhanced the importance of a heightened awareness, early diagnosis, and accurate typing of cardiac amyloidosis.

Course Director, Prem Soman, MD, MASNC on Tc-99m PYP Scan
to Diagnose ATTR Cardiac Amyloidosis
 

Venue

Innisbrook Golf & Spa Resort
36750 US Highway 19 N
Palm Harbor, FL  United States  34684
 

Innisbrook Patio
Book your hotel:
Hampton Inn
39284 US Hwy 19 N, Tarpon Springs, FL 34689
Phone: (727) 945-7755
As of 3/22/19, there were a few rooms still available.


Overall goal

The overall goal of this educational initiative is to increase the knowledge and awareness of ATTR-CM, among physicians, to improve diagnosis, timely referral to amyloid experts, and knowledge of current and emerging treatment options to improve outcomes of patients with ATTR-CM. 
 

Questions addressed by the workshop:

  • What clinical symptoms should raise level of suspicion for cardiac amyloidosis?
  • Why is it important to differentiate transthyretin cardiac amyloidosis from light chain cardiac amyloidosis?
  • Is there a diagnostic algorithm for the diagnosis and differentiation of ATTR-CA?
  • Are there standardized imaging protocols for diagnosing ATTR cardiomyopathy?
  • Is special training need to use Tc-99m PYP imaging?
  • What information is provided in the Tc-99m PYP imaging report?
  • What other diagnostic imaging tests are used in the evaluation of cardiac amyloidosis?

Learning Objectives

At the end of this course, participants will be able to:
  • Describe amyloidosis, including specific types, cardiac features, and disease burden
  • Identify barriers to patient identification and diagnosis
  • Summarize the diagnostic evaluation for CA, including the differential diagnosis
  • Provide details of Tc-99m PYP, including imaging protocol, semi-quantitative, and quantitative scoring, interpretation, and components of an appropriate report 
  • Demonstrate understanding of current and emerging treatments for patients with ATTR-CM

Cardiac Amyloidosis Agenda

Program Chair:

Dr. Prem Soman Prem Soman MD, PhD, MASNC, FACC, FRCP (UK) ​
Associate Professor of Medicine (Cardiology), and Clinical & Translational Science
Director, Nuclear Cardiology
Director, Multidisciplinary Cardiac Amyloidosis Center
Director, Advanced Cardiac Imaging Fellowship Division of Cardiology and The Heart and Vascular Institute
University of Pittsburgh Medical Center
 

Faculty:

Sharmila Dorbala, MD, MPH, FASNC
Mathew S. Maurer, MD
Frederick L. Ruberg, MD
 

Accreditation and Continuing Education

Credit The American Society of Nuclear Cardiology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Society of Nuclear Cardiology designates this live activity for a maximum of *3.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.
*Credits subject to change

View More Cardiac Amyloidosis Resources

Need statement

ATTR-CM, a type of CA, caused by the accumulation of misfolded transthyretin amyloid fibrils, leads to dysrhythmias and heart failure.1 Diagnosis is often  delayed and prognosis is poor.1,2 Transthyretin CA (ATTR-CA) has two main subtypes: hereditary/mutant ATTR, and senile, or wild-type, ATTR seen mostly in patients with advancing age.3 Differentiation of ATTR-CA from light chain CA is important  to ensure appropriate treatment and management ATTR-CM is an increasingly recognized etiology of heart failure with preserved ejection fraction 4 Traditional therapies for heart failure provide systematic treatment but do not address the underlying disease, and in some instances, may even be detrimental. Hence, early and accurate diagnosis is of critical importance.
 
Lack of awareness and suspicion of CA, and because clinical presentation often overlaps with other more common cardiovascular diseases, leads to missed and/or delayed diagnosis.5 The limited specificity of echocardiography and the need for endomyocardial biopsy, also delays diagnosis.

Non-invasive imaging with technetium-99m pyrophosphate and new and emerging therapies have the potential to diagnose the disease early and improve the long-term prognosis of patients with ATTR-CM.1,6,7,8 Clinicians need to distinguish the signs and symptoms of CA from other cardiovascular diseases, provide early and accurate diagnosis differentiating the subtype, and understand both current and emerging treatments to optimize patient care, limit organ damage and improve long-term outcomes.


Disclosure Policy

As an accredited provider of the Accreditation Council for Continuing Medical Education (ACCME), The American Society of Nuclear Cardiology (ASNC) adheres to the ACCME’s Standards for Commercial Support.  In compliance with these standards, it is ASNC’s policy to ensure balance, independence, objectivity, and scientific merit in all of its educational activities through the disclosure of relevant financial relationship with commercial companies and resolution of conflicts of interest.  The financial interest or relationships requiring disclosure are outlined in ASNC’s CME Conflict of Interest Policy.  All planners, reviewers and presenters involved with this activity were required to disclose any relevant financial relationships.
The American Society of Nuclear Cardiology has reviewed this activity’s faculty disclosures and resolved or managed all identified conflicts of interest.

Acknowledgement of Commercial Support
This activity is supported by an educational grant from Pfizer.

Travel Alert: Occasionally, outside companies try to defraud conference attendees by offering deals or assistance with hotel or travel bookings. ASNC is not associated with any outside companies. Please do not provide any credit card or confidential information; attendees should book with the hotel or airline service of their choice.​

References:
  1. Ruberg FL, et al. Circulation. 2012;126:1286-1300.
  2. Ruberg FL, et al. Am Heart J. 2012;164:222-228.
  3. Falk RH. Circulation. 2011;124:1079–1085.
  4. Vranian MN, et al. Curr Cardiol Rep. 2015;17:100.
  5. White JA, et al. Curr Cardiol Rep. 2016;18:77.
  6. Gillmore JD, et al. Circulation. 2016;133(24):2404-2412.
  7. Maurer M, et al. Circulation. 2017;135:1357-1377.
  8. Maurer MS, et al. N Eng J Med. 2018; 379:1007-1016.